1-16044378-C-CACACAT
Variant summary
Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP6_ModerateBS1BS2
The NM_000085.5(CLCNKB):c.-7-108_-7-107insACACAT variant causes a intron change involving the alteration of a non-conserved nucleotide. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.022 ( 67 hom., cov: 0)
Exomes 𝑓: 0.026 ( 627 hom. )
Failed GnomAD Quality Control
Consequence
CLCNKB
NM_000085.5 intron
NM_000085.5 intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.0860
Publications
2 publications found
Genes affected
CLCNKB (HGNC:2027): (chloride voltage-gated channel Kb) The protein encoded by this gene is a member of the family of voltage-gated chloride channels. Chloride channels have several functions, including the regulation of cell volume, membrane potential stabilization, signal transduction and transepithelial transport. This gene is expressed predominantly in the kidney and may be important for renal salt reabsorption. Mutations in this gene are associated with autosomal recessive Bartter syndrome type 3 (BS3). Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]
CLCNKB Gene-Disease associations (from GenCC):
- Bartter disease type 3Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet
- Bartter disease type 4BInheritance: AR Classification: STRONG Submitted by: G2P
- Bartter syndrome type 4Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- Gitelman syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -10 ACMG points.
BP6
Variant 1-16044378-C-CACACAT is Benign according to our data. Variant chr1-16044378-C-CACACAT is described in ClinVar as Benign. ClinVar VariationId is 3910069.Status of the report is criteria_provided_single_submitter, 1 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0223 (3366/151166) while in subpopulation NFE AF = 0.029 (1959/67648). AF 95% confidence interval is 0.0279. There are 67 homozygotes in GnomAd4. There are 1678 alleles in the male GnomAd4 subpopulation. Median coverage is 0. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 67 AR gene
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000085.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CLCNKB | NM_000085.5 | MANE Select | c.-7-108_-7-107insACACAT | intron | N/A | NP_000076.2 | P51801-1 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CLCNKB | ENST00000375679.9 | TSL:1 MANE Select | c.-7-108_-7-107insACACAT | intron | N/A | ENSP00000364831.5 | P51801-1 | ||
| CLCNKB | ENST00000906274.1 | c.-115_-114insACACAT | 5_prime_UTR | Exon 1 of 19 | ENSP00000576333.1 | ||||
| CLCNKB | ENST00000906263.1 | c.-7-108_-7-107insACACAT | intron | N/A | ENSP00000576322.1 |
Frequencies
GnomAD3 genomes AF: 0.0223 AC: 3365AN: 151058Hom.: 67 Cov.: 0 show subpopulations
GnomAD3 genomes
AF:
AC:
3365
AN:
151058
Hom.:
Cov.:
0
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.0262 AC: 15333AN: 585262Hom.: 627 AF XY: 0.0266 AC XY: 8249AN XY: 310550 show subpopulations
GnomAD4 exome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
15333
AN:
585262
Hom.:
AF XY:
AC XY:
8249
AN XY:
310550
show subpopulations
African (AFR)
AF:
AC:
88
AN:
17784
American (AMR)
AF:
AC:
461
AN:
32484
Ashkenazi Jewish (ASJ)
AF:
AC:
1074
AN:
18562
East Asian (EAS)
AF:
AC:
217
AN:
30428
South Asian (SAS)
AF:
AC:
1597
AN:
60128
European-Finnish (FIN)
AF:
AC:
1256
AN:
39192
Middle Eastern (MID)
AF:
AC:
79
AN:
2454
European-Non Finnish (NFE)
AF:
AC:
9762
AN:
353528
Other (OTH)
AF:
AC:
799
AN:
30702
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.403
Heterozygous variant carriers
0
506
1011
1517
2022
2528
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
112
224
336
448
560
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.0223 AC: 3366AN: 151166Hom.: 67 Cov.: 0 AF XY: 0.0227 AC XY: 1678AN XY: 73760 show subpopulations
GnomAD4 genome
AF:
AC:
3366
AN:
151166
Hom.:
Cov.:
0
AF XY:
AC XY:
1678
AN XY:
73760
show subpopulations
African (AFR)
AF:
AC:
221
AN:
41328
American (AMR)
AF:
AC:
274
AN:
15162
Ashkenazi Jewish (ASJ)
AF:
AC:
233
AN:
3460
East Asian (EAS)
AF:
AC:
27
AN:
5120
South Asian (SAS)
AF:
AC:
105
AN:
4746
European-Finnish (FIN)
AF:
AC:
375
AN:
10416
Middle Eastern (MID)
AF:
AC:
9
AN:
294
European-Non Finnish (NFE)
AF:
AC:
1959
AN:
67648
Other (OTH)
AF:
AC:
52
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
157
314
472
629
786
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
44
88
132
176
220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
ClinVar
ClinVar submissions
View on ClinVar Significance:Benign
Revision:criteria provided, single submitter
Pathogenic
VUS
Benign
Condition
-
-
1
not specified (1)
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.